BIOMAT Database Logo BIOMAT Database Logo

[Atherogenic properties of sera and low-density lipoproteins in patients with diabetes mellitus]. 1991

I A Sobenin, and V V Tertov, and T Koshinski, and E S Slavina, and I I Dedov, and A N Orekhov

The effects of sera and low density lipoproteins (LDL) on cholesterol levels were evaluated in cultured aortic intimal cells from patients with Types 1 and 2 diabetes mellitus. About 80% Type 1 diabetic patients' sera and 90% of Type 2 diabetic patients' sera caused a 1.5-4-fold increase in intracellular cholesterol levels. LDL isolated from atherogenic sera induced intracellular cholesterol accumulation. There was a close correlation between the atherogenic effect of the sera and LDL. The atherogenic properties of the sera and LDL from patients with diabetes mellitus were unassociated with the examinees' age. There was a relationship between the atherogenic serum effect and the compensation of carbohydrate metabolism in male patients with Type 1 diabetes mellitus. The atherogenic effect of the sera and LDL failed to increase in patients with Types 1 and 2 diabetes mellitus concurrent with coronary heart disease. The property of the sera to accumulate intracellular cholesterol is likely to be typical of diabetes mellitus and mainly due to disturbed LDL metabolism.

UI MeSH Term Description Entries
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D008297 Male Males
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001011 Aorta The main trunk of the systemic arteries. Aortas

Related Publications

I A Sobenin, and V V Tertov, and T Koshinski, and E S Slavina, and I I Dedov, and A N Orekhov
Atherogenic lipoproteins and diabetes mellitus.
January 2002, Journal of diabetes and its complications,
I A Sobenin, and V V Tertov, and T Koshinski, and E S Slavina, and I I Dedov, and A N Orekhov
[Atherogenic modification of low-density lipoproteins].
May 2016, Biomeditsinskaia khimiia,
I A Sobenin, and V V Tertov, and T Koshinski, and E S Slavina, and I I Dedov, and A N Orekhov
[Desialylated low density lipoproteins--atherogenic lipoproteins occurring in blood of patients with coronary atherosclerosis].
August 1990, Biulleten' eksperimental'noi biologii i meditsiny,
I A Sobenin, and V V Tertov, and T Koshinski, and E S Slavina, and I I Dedov, and A N Orekhov
Why are low-density lipoproteins atherogenic?
February 1994, The Western journal of medicine,
I A Sobenin, and V V Tertov, and T Koshinski, and E S Slavina, and I I Dedov, and A N Orekhov
[Non-enzymatically glycosylated low-density lipoproteins in diabetes mellitus].
January 1987, Vutreshni bolesti,
I A Sobenin, and V V Tertov, and T Koshinski, and E S Slavina, and I I Dedov, and A N Orekhov
Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus.
July 2003, The American journal of cardiology,
I A Sobenin, and V V Tertov, and T Koshinski, and E S Slavina, and I I Dedov, and A N Orekhov
Plasma lipoprotein composition and cholesteryl ester transfer from high density lipoproteins to very low density and low density lipoproteins in patients with non-insulin-dependent diabetes mellitus.
February 1996, Diabetic medicine : a journal of the British Diabetic Association,
I A Sobenin, and V V Tertov, and T Koshinski, and E S Slavina, and I I Dedov, and A N Orekhov
High-density and low-density lipoproteins and prevalence of vascular disease in diabetes mellitus.
April 1978, British medical journal,
I A Sobenin, and V V Tertov, and T Koshinski, and E S Slavina, and I I Dedov, and A N Orekhov
[Immune response against modified low-density lipoproteins in patients with non-insulin-dependent diabetes mellitus].
August 1997, Revista medica de Chile,
I A Sobenin, and V V Tertov, and T Koshinski, and E S Slavina, and I I Dedov, and A N Orekhov
Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype.
April 2001, Circulation,
Copied contents to your clipboard!